Envoy Medical, Inc. (COCH) · Nov 5, 2026 · Earnings

Envoy Medical earnings miss as Acclaim trial stays on track

Miss — Q3 revenue $66K vs ~$85K consensus

Envoy Medical’s third-quarter earnings missed the revenue bar, but its Acclaim cochlear-implant trial remains on schedule for key 2027 milestones.

Envoy Medical is a pre-commercial hearing-device company whose business now hinges on the investigational Acclaim fully implanted cochlear implant. The 56-patient pivotal trial is fully enrolled, the first 10 patients have reached 12-month follow-up, and the company is working toward a PMA submission after full-cohort data collection.

The earnings miss is the clear near-term negative. Third-quarter revenue was only $66,000 versus a published consensus of roughly $85,000, while the company remains far from meaningful commercial revenue. The miss matters less for operating momentum than it would for a mature business, but it confirms that this is still primarily a clinical-development story rather than a revenue story.

MetricQ3 2026Q3 2025Consensus
Net revenue (Income Statement)$66K$42K~$85K
Net loss attributable to common stockholders (Income Statement)$5.24M$7.75M
R&D expense (Income Statement)$3.077M$2.700M
Cash (Balance Sheet)$14.570M$3.739M*
Net cash used in operating activities (Cash Flow statement)$16.547M$12.516M

*December 31, 2025.

The Acclaim program is progressing, but this filing adds limited surprise. Management said the first 10 participants produced encouraging 12-month data, the full cohort passed three-month follow-up, and six-month follow-up has now been surpassed since quarter-end. It remains on track for all participants to complete 12-month visits by early in the second quarter of 2027. Those milestones are consistent with the timeline already disclosed before this report, so they reinforce execution rather than materially upgrade the story. 〔0〕

The financing improved near-term liquidity but did not remove the funding issue. Cash rose to $14.6 million after roughly $30.0 million of proceeds from issuing common stock, pre-funded warrants, and Series A warrants, but nine-month operating cash use increased to $16.5 million. The company is better funded for continued trial execution than it was at year-end, yet it remains dependent on capital markets or another funding source before commercialization. The filing does not provide a new explicit runway estimate.

The cost structure reflects a company investing behind the trial, not scaling sales. R&D increased to $3.1 million as follow-up and regulatory work expanded, while sales and marketing fell to $157,000 because field clinical specialists were reassigned to trial support.

Bottom line: This is a slight earnings miss layered onto an otherwise on-schedule clinical program. The filing keeps the Acclaim story intact, but it does not provide a new clinical breakthrough or eliminate the company’s ongoing need for financing before approval and commercialization.

What to watch next

All 56 participants complete 12-month visits, early Q2 2027

Original filing on SEC EDGAR

More Envoy Medical, Inc. news

Envoy Medical earnings miss as Acclaim trial stays on track | COCH Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.